Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eton Pharmaceuticals, Inc. (NASDAQ: ETON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eton’s Form 8-K filings in 2025 cover topics such as quarterly financial results, changes in independent registered public accounting firms, index inclusion, product acquisitions, and key regulatory milestones for its rare disease portfolio.
For example, a November 6, 2025 Form 8-K furnishes a press release announcing financial results for the quarter ended September 30, 2025 and explains the company’s use of non-GAAP measures like Adjusted EBITDA. Other 8-K filings describe the FDA’s acceptance of the New Drug Application for ET-600, a proprietary desmopressin oral solution, and Eton’s addition to the Russell 2000 and Russell 3000 indexes. An 8-K/A filed on November 18, 2025 provides historical financial statements and unaudited pro forma condensed combined financial information related to the acquisition of INCRELEX.
Through these filings, investors can review Eton’s reported net revenues, product sales trends, research and development spending on programs such as ET-600, ET-700, and ET-800, and general and administrative expenses associated with commercial launches. Filings also document governance and audit matters, including the June 20, 2025 8-K reporting the dismissal of Crowe LLP and the appointment of Grant Thornton LLP as the new independent auditor.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the main points of complex documents, such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly understand what each filing means for Eton’s rare disease strategy, financial position, and regulatory progress, and can also monitor insider and other ownership-related filings like Forms 3, 4, and 5 when available.
Eton Pharmaceuticals director Norbert G. Riedel reported new equity compensation grants. On January 12, 2026, he was granted options to purchase 12,196 shares of common stock at an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are scheduled to be fully vested and exercisable by January 12, 2027.
On the same date, he also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in four equal annual installments beginning January 12, 2027, contingent on his continued service with the company on each vesting date. Following these grants, he beneficially owns 294,253 derivative securities directly.
Eton Pharmaceuticals director Adams Jennifer McKie reported new equity awards. On January 12, 2026, she received an employee stock option grant for 12,196 shares with an exercise price of $15.47 per share. These options vest quarterly over 12 months from the grant date and are expected to be fully vested and exercisable by January 12, 2027.
She also received 7,757 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock. The RSUs vest in one annual installment beginning January 12, 2027, contingent on her continued service with the company on the vesting date(s). Following these grants, she beneficially owns 170,329 derivative securities related to stock options and 178,086 derivative securities related to RSUs, all held directly.
Eton Pharmaceuticals director Charles J. Casamento reported new equity awards. On January 12, 2026, he received an employee stock option covering 12,196 shares of Eton common stock with an exercise price of $15.47 per share. According to the filing, these option shares vest quarterly over 12 months from the grant date and become fully vested and exercisable on January 12, 2027.
On the same date, he was also granted 7,757 restricted stock units. Each RSU represents a contingent right to receive one share of Eton common stock. These RSUs vest in a single annual installment beginning January 12, 2027, conditioned on his continued employment with the company on the vesting date. Following these grants, he beneficially owned 295,171 derivative securities related to options and 302,928 derivative securities related to restricted stock units.
Eton Pharmaceuticals director Paul V. Maier reported new equity awards. On January 12, 2026, he received an employee stock option for 12,196 shares of common stock at a $15.47 exercise price. These options vest quarterly over 12 months from the grant date and are fully exercisable on January 12, 2027.
He also received 7,757 restricted stock units, each representing a contingent right to one share of Eton common stock. These RSUs vest in one annual installment beginning January 12, 2027, contingent on his continued employment with the company. After these derivative awards, the filing shows 286,496 derivative securities following the option grant and 294,253 following the RSU grant, all held directly.
Eton Pharmaceuticals Chief Commercial Officer Erdogan-Trinkaus Ipek reported new equity awards. On January 12, 2026, the executive received an employee stock option for 40,655 shares of common stock at an exercise price of $15.47 per share. These options vest in 48 equal monthly installments from the grant date and become fully vested and exercisable on January 12, 2030.
The filing also shows a grant of 25,856 restricted stock units (RSUs), each representing one share of ETON common stock. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on continued employment on each vesting date. After these grants, the reporting person beneficially owns 123,878 derivative securities tied to options and 149,734 derivative securities tied to RSUs.
Eton Pharmaceuticals President & CEO Sean Brynjelsen, also a director and 10% owner, reported multiple equity transactions. On January 1, 2026, 5,015 shares of common stock were disposed of at a weighted average price of $15.39, with shares withheld by the company to satisfy taxes upon vesting of restricted stock units, leaving him with 2,889,266 common shares held directly.
On January 12, 2026, he was granted an employee stock option for 158,046 shares at an exercise price of $15.47, vesting in 48 equal monthly installments until fully vested and exercisable on January 12, 2030, and expiring January 11, 2036. He also received 100,517 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning January 12, 2027, contingent on continued employment.
Eton Pharmaceuticals chief business officer David Krempa reported new equity awards and related tax withholding transactions. On January 12, 2026, he was granted 40,655 employee stock options with an exercise price of $15.47 per share, vesting in 48 equal monthly installments until fully vested and exercisable on January 12, 2030, and expiring on January 11, 2036. He also received 25,856 restricted stock units, each representing a right to one share of Eton common stock, vesting in four equal annual installments beginning January 12, 2027, contingent on continued employment. On January 14, 2026, 1,942 shares of common stock were withheld at $15.62 per share to cover taxes on RSU vesting, leaving 630,238 common shares beneficially owned directly, 670,893 derivative securities from options, and 696,749 derivative securities including RSUs.
Eton Pharmaceuticals Chief Financial Officer James R. Gruber reported routine equity compensation activity and related tax withholding. On January 12, 2026, he received an option grant for 40,655 shares of common stock at an exercise price of $15.47 per share, scheduled to vest in 48 equal monthly installments until January 12, 2030. He also received 25,856 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning January 12, 2027, contingent on continued employment.
On January 14, 2026, 2,293 shares of common stock were withheld and sold at a weighted average price of $15.47 to satisfy withholding taxes upon vesting of restricted stock units. After this transaction, Gruber beneficially owned 213,420 shares of common stock directly.
Form 144 discloses a planned sale of restricted or control securities. The filer intends to sell 1,942 shares of common stock through Raymond James & Associates on the NASDAQ, with an aggregate market value of $30,334.04. The filing notes that 26,820,000 shares of this class were outstanding.
The securities to be sold were acquired as a grant from the issuer on 01/13/2026, with a stated amount of 6,469 shares and a cash payment date of 01/14/2026. The notice also reports that David Krempa sold 6,264 common shares on 12/12/2025 for gross proceeds of $106,460.00. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Eton Pharmaceuticals insider plans a modest stock sale under Rule 144. A notice was filed to sell 2,293 shares of common stock through Raymond James & Associates, with an aggregate market value of $35,483.96, on or about 01/14/2026 on the NASDAQ. The filing notes that 26,820,000 shares of the issuer’s common stock were outstanding.
The securities to be sold are part of 6,469 common shares acquired on 01/13/2026 via a grant from the issuer, with cash noted as the form of payment dated 01/14/2026. Over the prior three months, James R. Gruber sold 4,524 common shares on 12/12/2025 for gross proceeds of $76,883.00. The signer represents that they are not aware of any undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Eton Pharmaceuticals (ETON)?
What is the market cap of Eton Pharmaceuticals (ETON)?
